• KOL
    • Sickle Cell Disease
    • Elliott P Vichinsky
    • Elliott P Vichinsky: Influence Statistics

      Elliott P Vichinsky

      Elliott P Vichinsky

      Show email address

      Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, UNITED STATES | Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Elliott P Vichinsky:Expert Impact

      Concepts for whichElliott P Vichinskyhas direct influence:Sickle cell disease,Sickle cell,Sickle cell anemia,Cell disease,Iron overload,Pulmonary hypertension,North america,Acute chest syndrome.

      Elliott P Vichinsky:KOL impact

      Concepts related to the work of other authors for whichfor which Elliott P Vichinsky has influence:Sickle cell disease,Iron overload,Pulmonary hypertension,Acute chest syndrome,Cell anemia,Patients scd,Fetal hemoglobin.

      KOL Resume for Elliott P Vichinsky

      Year
      2022

      Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, UNITED STATES

      Department of Hematology/Oncology, UCSF-Benioff Children's Hospital Oakland, Oakland, CA, USA.

      2021

      UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.

      Pediatric Hematology Oncology, University of California, San Francisco, CA.

      Division of Hematology/Oncology, University of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, USA

      2020

      UCSF Benioff Children's Hospital, Oakland, CA

      2019

      From the University of California, San Francisco (UCSF) Benioff Children's Hospital Oakland, Oakland (E.V.), and Global Blood Therapeutics, South San Francisco (C.C.H., J.L.-G., M.T., A.I., B.T.) - both in California; the University of Tennessee Health Science Center at Memphis, Memphis (K.I.A.); Cincinnati Children's Hospital and University of Cincinnati, Cincinnati (R.E.W.); Kenya Medical Research Institute, Kisumu, Kenya (V.N.); Cairo University, Cairo (A.E.-B.), and the Pediatric Department and Clinical Research Center, Faculty of Medicine (H.H.), and the Faculty of Medicine (A.E.), Alexandria University, Alexandria - all in Egypt; Brigham and Women's Hospital and Harvard Medical School, Boston (M.M.A.); Sultan Qaboos University, Muscat, Oman (S.A.); Emory University and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta (R.C.B.); New York-Presbyterian/Columbia University Medical Center, New York (D.L.D.); Barts Health NHS Trust (P.T.), Homerton University Hospital NHS Foundation Trust (D.A.T.), and Guy's and St. Thomas' NHS Foundation Trust and King's College (J.H.) - all in London; the University of Illinois at Chicago, Chicago (V.R.G.); the University of Alabama at Birmingham, Birmingham (J.K.); and the American University of Beirut Medical Center, Beirut, Lebanon (M.R.A.).

      Children’s Hospital Oakland Research Institute, Oakland, CA 94609, USA

      UCSF Benioff Children's Hospital Oakland, Oakland, CA

      2018

      Department of Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, Oakland, California

      Hematology Oncology, UCSF Benioff Children’s Hospital Oakland, 747 52nd Street, Oakland, CA 94609, USA

      2017

      UCSF Benioff Children's Hospital, Oakland, California, United States

      Department of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA

      2016

      UCSF Benioff Children's Hospital Oakland CA USA

      Division of Hematology/Oncology University of California San Francisco Benioff Children's Hospital Oakland Oakland California

      2015

      Research Center, Benioff Children’s Hospital Oakland, Oakland, California, USA

      UCSF Benioff Children’s Hospital, Oakland, University of California, San Francisco, CA,

      2014

      Children's Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA

      Department of Hematology/Oncology, Children’s Hospital & Research Center Oakland, Oakland, CA

      2013

      Centers for Disease Control and Prevention Atlanta Georgia

      Department of Hematology and Oncology, Children’s Hospital and Research Center Oakland, Oakland, CA, USA

      From the Pediatric Clinical Research Center, Children’s Hospital and Research Center, Oakland, California.

      Children's Hospital Los Angeles Los Angeles California

      Weill Medical College of Cornell University New York New York

      2012

      Department of Hematology, Oakland, California

      Hematology/Oncology, Children's Hospital and Research Center Oakland, Oakland, CA 94609, USA.

      Children's Hospital & Research Center Oakland, Oakland, CA;

      2011

      William H. Eilinger Professor and Chair, Department of Pediatrics; Professor, Department of Neurology; Pediatrician-in-Chief, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, New York

      James B. Duke Professor and Chair, Department of Pediatrics, Duke University School of Medicine; Chief Medical Officer, Duke Children's Hospital and Health Center, Durham, North Carolina

      Hematology/Oncology Department, Children's Hospital & Research Center Oakland, Oakland, CA

      Professor and Schotanus Family Endowed Chair of Pediatrics; Pediatrician-in-Chief, Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan

      Nonprofit Healthcare and Educational, Consultants to Medical Institutions, Santa Barbara, California

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Elliott P Vichinsky is among the top experts in the world.
      Concept World rank
      inherited blood disease #1
      sickle cell scd #1
      trials deferasirox #1
      chronic ecp patients #1
      hemoglobin syndromes hemoglobin #1
      scd patients acs #1
      patients voxelotor #1
      extended phenotypic matching #1
      thalassemia north #1
      syndrome respiratory failure #1
      phenotypically matched blood #1
      discontinuing penicillin #1
      endocrinopathy thal #1
      authors arg supplementation #1
      serum ferritin mds #1
      orthopedic disease majority #1
      dose levels voxelotor #1
      oral supplementation clinical #1
      transfusion therapy risks #1
      cohort scd #1
      hemoglobinopathies review #1
      early avn scd #1
      morbidity iron overload #1
      growth rate clinical #1
      treatment alphathalassemia #1
      thal gonadal failure #1
      anemia preschool delivery #1
      6 years deferasirox #1
      united states thalassemia #1
      sct status respondents #1
      management ntdt #1
      transfused patients thalassaemia #1
      mds dba #1
      decompression physical therapy #1
      mds disease groups #1
      pulmonary hypertension thalassaemia #1
      hb betathalassaemia #1
      patients impending acs #1
      subjects splenectomized patients #1
      early avn #1
      lglutamine placebo #1
      complications thalassemia #1
      thalassemia versus #1
      ray 10 patients #1
      pht children #1
      diseases hemosiderosis #1
      hb sodium phenylbutyrate #1
      action pharmacokinetics study #1
      txscd thal #1
      thalassemia adherence #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Elliott P Vichinsky

      KOL-Index: 23003

      BACKGROUND: Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous infusions. This can lead to reduced quality of life and poor adherence, resulting in increased morbidity and mortality in iron-overloaded patients with beta-thalassemia. Deferasirox is an orally administered iron chelator that has been approved for ...

      Known for Patients Dfo | Deferasirox Study | Iron Overload | Treatment Ict | Reported Outcomes
      KOL-Index: 17340

      BACKGROUND: Blood transfusions prevent recurrent stroke in children with sickle cell anemia, but the value of transfusions in preventing a first stroke is unknown. We used transcranial Doppler ultrasonography to identify children with sickle cell anemia who were at high risk for stroke and then randomly assigned them to receive standard care or transfusions to prevent a first stroke.

      METHODS: To enter the study, children with sickle cell anemia and no history of stroke had to have ...

      Known for Transcranial Doppler | Transfusions Children | Sickle Cell | Transfusion Patients | Risk Stroke
      KOL-Index: 17034

      BACKGROUND: Osteonecrosis of the femoral head is a common complication in patients with sickle cell disease, and collapse of the femoral head occurs in 90% of patients within five years after the diagnosis of the osteonecrosis. However, the efficacy of hip core decompression to prevent the progression of osteonecrosis in these patients is still controversial.

      METHODS: In a prospective multicenter study, we evaluated the safety of hip core decompression and compared the results of ...

      Known for Physical Therapy | Core Decompression | Femoral Head | Sickle Cell Disease | Osteonecrosis Patients
      KOL-Index: 15404

      CONTEXT: Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes.

      OBJECTIVE: To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality.

      DESIGN: Plasma amino acid levels, ...

      Known for Pulmonary Hypertension | Sickle Cell Disease | Arginine Metabolism | Cell Arginase | Ornithine Citrulline
      KOL-Index: 14467

      Transfusion therapy for sickle cell anemia is limited by the development of antibodies to foreign red cells. To evaluate the frequency and risk factors associated with such alloimmunization, we determined the transfusion history, red-cell phenotype, and development of alloantibodies in 107 black patients with sickle cell anemia who received transfusions. We compared the results with those from similar studies in 51 black patients with sickle cell disease who had not received transfusions ...

      Known for Sickle Cell Anemia | Crossmatching Child Child | Donors Patients | Racial Differences | Development Alloantibodies
      KOL-Index: 14412

      Stroke occurs in 7-8% of children with Sickle Cell Disease (Hb SS) and is a major cause of morbidity. Rates of recurrence have been reduced from 46-90% to less than 10% through chronic blood transfusions. Prevention of first stroke, however, would be preferable because even one stroke can cause irreversible brain injury. Transcranial Doppler (TCD) ultrasound can detect arterial blood flow rates associated with subsequent stroke risk. By combining TCD screening and a potentially effective ...

      Known for Stroke Prevention Trial | Cell Anemia | Cerebral Infarction | Tcd Screening | Sickle Humans
      KOL-Index: 13879

      PURPOSE: To compare the results of standardized magnetic resonance imaging (MRI) of the brain and transcranial Doppler (TCD) ultrasonography of cerebral arteries in school-aged children with sickle cell disease to determine the correlation between these two different neurodiagnostic tests.

      PATIENTS AND METHODS: Data were analyzed from 78 children with sickle cell disease (mean age 11 yrs) who participated in both the Cooperative Study of Sickle Cell Disease (CSSCD) and the Stroke ...

      Known for Sickle Cell Disease | Transcranial Doppler | Magnetic Resonance | Central Nervous | Overt Stroke
      KOL-Index: 13651

      OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in regularly transfused patients aged 3-81 yrs with myelodysplastic syndromes (MDS; n = 47), Diamond-Blackfan anaemia (DBA; n = 30), other rare anaemias (n = 22) or beta-thalassaemia (n = 85). Dosage was determined by baseline liver iron concentration (LIC).

      RESULTS: In patients with baseline LIC > or = 7 mg Fe/g dry weight, deferasirox initiated at 20 or 30 mg/kg/d produced statistically ...

      Known for Myelodysplastic Syndromes | Deferasirox Mds | Lic Patients | Transfusional Iron Intake | Dependent Anaemias
      KOL-Index: 13628

      We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years. The primary objective was to evaluate deferasirox safety compared with DFO; long-term efficacy and safety of deferasirox was also assessed. We also report, for the first time, the safety and pharmacokinetics of deferasirox in patients concomitantly ...

      Known for Patients Deferasirox | Sickle Cell | Efficacy Safety | 2 Years | Iron Overload
      KOL-Index: 13578

      Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle cell disease often have abnormal baseline renal function, the primary objective of this randomised, open-label, phase II trial was to evaluate the safety and tolerability of deferasirox in comparison with deferoxamine in this population. Assessment of efficacy, as measured by ...

      Known for Transfusional Iron Overload | Deferasirox Deferoxamine | Sickle Cell Disease | Oral Iron | Serum Creatinine

      Thalassemia


      [ PUBLICATION ]
      KOL-Index: 12864

      New developments in the epidemiology, treatment and prognosis of thalassemia have dramatically altered the approach to the care of affected patients, and these developments are likely to have an even greater impact in the next few years. Demographic changes have required an awareness and understanding of the unique features of thalassemia disorders that were previously uncommon in North America but are now seen more frequently in children and recognized more consistently in adults. New ...

      Known for Patients Thalassemia | North America | Chelation Therapy | Iron Chelators | Cardiac Disease
      KOL-Index: 12623

      BACKGROUND/AIMS: There is increasing evidence demonstrating the value of transfusions in sickle cell disease (SCD). However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that can negatively impact quality of life and adherence to treatment.

      METHODS: As part of a phase II trial, SCD patient-reported outcomes were evaluated. One hundred and ninety-five patients were randomized (2:1) to receive oral ...

      Known for Deferasirox Deferoxamine | Sickle Cell | Patients Scd | Transfusional Hemosiderosis | Quality Life
      KOL-Index: 12497

      BACKGROUND: Providing home care for a child with a chronic illness can be stressful for the family. The purpose of this paper is to examine patterns of caregiving and the associated psychological impact on maternal caregivers of children with sickle cell disease (SCD).

      PROCEDURE: Fourteen maternal caregivers of children with SCD were interviewed as part of a larger study of maternal caregivers of children with chronic illness. Forty-four caregivers of children with HIV and 36 caregivers ...

      Known for Caregivers Children | Sickle Cell | Chronic Illness | Time Child | Stress Psychological
      KOL-Index: 12318

      PURPOSE: Blood pressure in individuals who have sickle cell disease has been reported to be lower than published normal values. We determine whether and to what degree this is true, using data obtained as part of a large natural history study.

      PATIENTS AND METHODS: Blood pressure was measured annually for 3,317 subjects with sickle cell disease who were 2 years old or older. Values obtained were compared with those reported by the National Health and Nutrition Examination Survey I and II ...

      Known for Blood Pressure | Sickle Cell Anemia | Cell Disease | Relative Hypertension | Increased Risk Stroke

      Key People For Sickle Cell Disease

      Top KOLs in the world
      #1
      Elliott P Vichinsky
      sickle cell disease iron overload pulmonary hypertension
      #2
      Martin H Steinberg
      sickle cell anemia fetal hemoglobin cell disease
      #3
      Samir K Ballas
      sickle cell disease iron overload cell anemia
      #4
      Oswaldo L Castro
      sickle cell disease pulmonary hypertension iron overload
      #5
      Russell E Ware
      sickle cell anemia children sca hydroxyurea therapy
      #6
      Mark T Gladwin
      sickle cell disease pulmonary hypertension nitric oxide

      Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, UNITED STATES | Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA | Department of Hematology/Oncology, UCSF-Benioff Children's Hospital Oakland

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.